| LORCASERIN HYDROCHLORIDE | EISAI INC | ||
| 20 mg; Tablet, Extended Release |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
Less Than 5
|
None | ||
| None | None | ||
| An adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients | |||
|
Yes
| |||
| Belviq XR | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **** | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ********-******* ****** ***** ** *-**** ******** ****** *** ****** ********** | ***** ******** ********** | ***** ******** ********** | ***** ******** ********** | ***** ******** ********** | ***** ******** ********** | ***** ******** ********** | ********* *** ********* *-************ | ***** ******** ********** | ***** ******** ********** | *********** ***** ** (*)-*-******-*-******-*,*,*,*-**********-**-*-*********** ************* | ********* *** ********* *-************ | *********** ***** ** (*)-*-******-*-******-*,*,*,*-**********-**-*-*********** ************* | ************** ** ** ****-******* ******** ** *********** **** ***** ********** | ****** ** ****** ********** | ************** ** ** ****-******* ******** ** *********** **** ***** ********** |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| **** | *** \ ********* | **** *, **** | ******* | **** | ***** ***** ****(***** ******) |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|